Johnson & Johnson's Icotyde Receives FDA Approval for Psoriasis Treatment

On March 18, 2026, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (J&J) oral medication, Icotyde (icotrokinra), for the treatment of moderate-to-severe plaque psoriasis in patients aged 12 and older. This approval marks Icotyde as the first oral interleukin-23 (IL-23) receptor antagonist, providing a new treatment option for an estimated 8 million Americans suffering from this chronic autoimmune condition, which causes itchy and inflamed skin patches.

ReutersFiercePharmaCNBCPharmaphorumBenzinga

Icotyde is designed to be taken once daily, offering a convenient alternative to existing injectable therapies such as J&J's Tremfya and AbbVie's Skyrizi. Analysts have noted that Icotyde has "blockbuster potential," with projections estimating peak annual sales could exceed $5 billion. The drug's efficacy was demonstrated in clinical trials, where approximately 70% of patients achieved clear or almost clear skin, significantly outperforming competitors like Bristol Myers Squibb's Sotyktu.

Reuters

The approval of Icotyde is expected to intensify competition in the psoriasis treatment market, which has been dominated by injectable biologics. Analysts from Guggenheim predict rapid market uptake for Icotyde due to its favorable safety profile and the simplicity of a once-daily pill. In contrast, AbbVie’s Skyrizi saw its stock drop by over 4% following the announcement, reflecting concerns about increased competition.

Benzinga

Jennifer Taubert, chairman of J&J Innovative Medicine, emphasized the transformative potential of Icotyde, stating, "We believe having the type of profile that Icotyde has in a simple, once-daily oral pill, we think it's going to be an absolute game changer for patients." David Lee, J&J's global head of immunology, noted the importance of complete skin clearance and the simplicity of the medication, reinforcing the drug's appeal to patients who may be hesitant to use injections.

CNBC

Despite the optimism surrounding Icotyde, some analysts caution that the market for psoriasis treatments is complex. Concerns have been raised about the pricing and accessibility of Icotyde, as J&J has not yet disclosed its cost. Additionally, while Icotyde is expected to capture market share, it remains to be seen how it will perform against established injectables that have already gained patient trust.

CNBC

Johnson & Johnson plans to expand the use of Icotyde beyond psoriasis, with ongoing studies for conditions such as psoriatic arthritis, ulcerative colitis, and Crohn's disease. The company is optimistic about Icotyde's potential to become a cornerstone of its immunology portfolio, which generated $15 billion in sales in 2025.

Reuters

• "To be able to have something that is relatively simple, that offers that level of clearance, trusted safety profile, and in a simple pill, we think is going to be revolutionary." — Jennifer Taubert, Chairman of J&J Innovative Medicine

CNBC

• "We see Icotyde as becoming the first-line systemic therapy for psoriasis patients." — David Lee, Global Head of Immunology at J&J

FiercePharma

• "The key now will be Icotyde's commercial uptake, which we think will be quite rapid given its clinical profile as a potential best oral option for patients with psoriasis." — Vamil Divan, Guggenheim Analyst

Reuters

The approval of Icotyde represents a significant advancement in psoriasis treatment, potentially reshaping the landscape of available therapies and offering new hope to patients seeking effective management of their condition.

FiercePharma